Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.05 NOK | +0.07% | +0.50% | -34.35% |
Sales 2024 * | 157M 14.54M | Sales 2025 * | 190M 17.58M | Capitalization | 4.58B 424M |
---|---|---|---|---|---|
Net income 2024 * | -613M -56.74M | Net income 2025 * | -735M -68.03M | EV / Sales 2024 * | 21.2 x |
Net cash position 2024 * | 1.25B 116M | Net cash position 2025 * | 1.01B 93.4M | EV / Sales 2025 * | 18.8 x |
P/E ratio 2024 * |
-7.54
x | P/E ratio 2025 * |
-6.76
x | Employees | 172 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55% |
Latest transcript on Nykode Therapeutics
1 day | +0.07% | ||
1 week | +0.50% | ||
Current month | +5.09% | ||
1 month | +7.83% | ||
3 months | -25.70% | ||
6 months | -17.84% | ||
Current year | -34.35% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 146 M€ | -2.53% | - | |
0.00% | 25 M€ | -3.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 14.05 | +0.07% | 843 781 |
24-05-10 | 14.04 | +3.16% | 586,486 |
24-05-08 | 13.61 | -3.20% | 733,185 |
24-05-07 | 14.06 | +0.57% | 473,350 |
24-05-06 | 13.98 | +1.01% | 839,911 |
Real-time Oslo Bors, May 13, 2024 at 11:04 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.35% | 423M | |
+4.97% | 109B | |
+11.27% | 105B | |
-0.38% | 22.25B | |
-12.21% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.85% | 16.85B | |
+4.51% | 13.76B | |
+34.99% | 12.46B |
- Stock Market
- Equities
- VACC Stock